1 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239–1242.
2 Smriti Mallapaty How deadly is the coronavirus? Scientists are close to an answer Nature. 2020;582, 467-468. doi: 10.1038/d41586-020-01738-2, Available from:https://www.nature.com/articles/d41586-020-01738-2 (Cited 8 August 2020)
3 Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, Et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill.2020;25(12): pii=2000256. https://doi.org/10.2807/1560-7917.ES.2020.25.12.2000256
4 Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis [published correction appears in Lancet Infect Dis. 2020 Apr 15;:] [published correction appears in Lancet Infect Dis. 2020 May 4;:]. Lancet Infect Dis.2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7
5 World Health Organization. Coronavirus. Available at: https://www.who.int/health- topics/coronavirus#tab=tab_1 (Cited 6 August 2020)
6 Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published correction appears in Lancet Respir Med. 2020 Jun;8(6):e54]. Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
7 Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62 https://doi.org/10.1016/S0140-6736(20)30566-3
8 Istituto Superiore di Sanità. Report sulle caratteristiche dei pazienti deceduti positivi a COVID- 19 in Italia Il presente report è basato sui dati aggiornati al 13 Marzo 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_17_marzo-v2.pdf (Accessed 6 August 2020)
9 Doorn-Khosrovani SBW, Roy AP. Rapid Response: COVID-19: learning from the claim data of those who were severely affected but also from their asymptomatic household members.Available at: https://www.bmj.com/content/368/bmj.m1086/rr-1 (Accessed 6 August 2020)
10 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S Et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;doi: 10.1001/jamainternmed.2020.0994.
11 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z Et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.
12 Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin– angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;382:1653–1659.
13 Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA 2020;doi:10.1001/jama.2020.4812.
14 Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids 2015;47:693–705.
15 Hoffmann M, Kleine-Weber H, Schroeder S, Kru¨ger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–280.
16 Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260–1263.
17 Chao Gao, Yue Cai, Kan Zhang, Lei Zhou, Yao Zhang, Xijing Zhang, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study, European Heart Journal. 2020; 41(22):2058–2066. https://doi.org/10.1093/eurheartj/ehaa433
18 Bowale A, Abayomi A, Idris J, Omilabu S, Abdus-Salam I, Adebayo B, et al. Clinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria. Pan Afr Med J. 2020 May; 35(2): 24. doi:10.11604/pamj.supp.2020.35.2.23262
19 Paudel SS. A meta-analysis of 2019 novel coronavirus patient clinical characteristics and comorbidities. Research Square. 2020. 10.21203/rs.3.rs-21831/v1 [Accessed April 18, 2020, https://www.researchsquare.com/article/rs-21831/v1].
20 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038].Lancet.2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
21 Ernesto L Schiffrin, John M Flack, Sadayoshi Ito, Paul Muntner, R Clinton Webb, Hypertension and COVID-19, American Journal of Hypertension. 2020:33(5);373–374 https://doi.org/10.1093/ajh/hpaa057
22 Arjun Kanwal A, Agarwala A, Martin LW, Handberg EM, Yang E. COVID-19 and Hypertension: What We Know and Don't Know. American College of Cardiology Expert Analysis. https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and- hypertension (Accessed 7 August 2020)
23 Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;doi: 10.1001/jamacardio.2020.0950.
24 Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. Impact of antihypertensive treatments in COVID-19 2065. Downloaded from https://academic.oup.com/eurheartj/article-abstract/41/22/2058/5851436 on 29 July 2020
25 Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. 2020;323(18):1769–1770. doi:10.1001/jama.2020.4812
26 Hypertension ECo. Position Statement of the ESC Council on Hypertension on ACE Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on- Hypertension-(CHT)/News/position-statement-of-the-esc-councilon-hypertension-on-ace- inhibitors-and-ang.